Topic Cancer
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Management of Peristomal Pyoderma Gangrenosum in IBD
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: DCR0720APublished: July 2020Expires: 7/1/2023Sources: Diseases of the Colon and RectumDetailsRequired Passing Score: 5/4 (125%)Sub-Specialties: Colon and Rectal -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Rising Role of the Microbiome in Cancer
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0520Published: May 2020Expires: 4/30/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Cancer , Microbiome -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Rising Role of the Microbiome in Cancer ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0520Published: May 2020Expires: 4/30/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Cancer , Microbiome -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Anal Melanoma: A Rare Perianal Tumor With a Poor Prognosis
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: DCR0520APublished: May 2020Expires: 4/27/2023Sources: Diseases of the Colon and RectumDetailsRequired Passing Score: 5/6 (83%)Sub-Specialties: Colon and Rectal -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Evaluation and Management of Hemorrhoids
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: DCR0420APublished: April 2020Expires: 4/1/2023Sources: Diseases of the Colon and RectumDetailsRequired Passing Score: 3/4 (75%)Sub-Specialties: Colon and Rectal -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Antibody Drug Conjugates: New Weapons Against Cancer
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0320Published: March 2020Expires: 3/31/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Cancer , Drug Update -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Antibody Drug Conjugates: New Weapons Against Cancer ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0320Published: March 2020Expires: 3/31/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Cancer , Drug Update -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Complicated Diverticulitis
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: DCR0120APublished: JanuaryExpires: 1/1/2023Sources: Diseases of the Colon and RectumDetailsRequired Passing Score: 5/6 (83%)Collections: Diseases of the Colon & Rectum (Collection)Sub-Specialties: Colon and Rectal -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Study Tracks Accelerating Use of Biomarkers in Cancer Clinical Trials
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT1219Published: December 2019Expires: 12/3/2021Sources: Oncology TimesDetails -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Study Tracks Accelerating Use of Biomarkers in Cancer Clinical Trials ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN1219Published: December 2019Expires: 12/3/2021Sources: Oncology TimesDetails